At a Glance
Women’s Health (osteoporosis)
NDA has been submitted, awaiting final FDA approval.
Applications In Development:
APRELA® (bazedoxifene in combination with PREMARIN®) is a progesterone-free treatment for menopausal symptoms. In July 2009 Phase III data showing that APRELATM significantly reduced the frequency and severity of hot flushes and improved measures of vaginal atrophy when compared to placebo was published in the journal Fertility and Sterility. An initial NDA is expected to be filed in the second half of 2010.